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Interleukin (IL)-15N72D-superagonist-complexed with
IL15Ra-Fc fusion protein (IL15-SA/IL15Ra-Fc, also
known as ALT-803) has been reported to have greater
anti-myeloma activity, due to its increased in vivo half-life
and unique tissue biodistribution, than native IL-15 alone
in murine models. In order to test the anti-tumor efficacy
of IL15-SA/IL15Ra-Fc in a non-hematologic murine
cancer model, we examined the monotherapy effect of
IL15-SA/IL15Ra-Fc in non-tumor bearing mice and in the
4T1-breast tumor model. In non-tumor bearing Balb/c
mice, IL15-SA/IL15Ra-Fc (1 µg i.p.), a 10-fold increase
occurred in NK cells followed by CD8+ T cells (3-fold),
both peaking on Day 3 post treatment. In examining NK
cell population subsets, the greatest significant change was
in high effector (CD11b+, CD27hi) NKs as compared with
terminal effector (CD11b+, CD27lo) NKs on Day 3 post
IL15-SA/IL15Ra-Fc-treatment, leading to increased NK
function on a per-cell basis. CD8 subset analysis deter-
mined that IL15-SA/IL15Ra-Fc significantly increased
IL15-responding, memory (CD122+, CD44+) CD8+
T cells, in particular those having the innate (NKG2D+,
PD1-) phenotype. In 4T1 tumor bearing mice, IL15-SA/
IL15Ra-Fc induced significant anti-metastatic activity, and
thus consequently resulted in a longer median survival of
IL15-SA/IL15Ra-Fc-treated mice following surgical resec-
tion of the primary tumor. Finally, T cell depletion
revealed that the anti-metastatic property of IL15-SA/
IL15Ra-Fc was dependent on CD8+ T cells and not CD4+
T cells. Altogether, these studies showed for the first time
that IL15-SA/IL15Ra-Fc a) promoted the development of
high effector NKs, b) enhanced per-cell function of NKs,
and c) played a vital role in reducing tumor metastasis and
ultimately survival.
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